Table 1. High lightened studies of platinum based chemotherapy as first line treatment of malignant pleural mesothelioma, (EAP, International Expanded Access Program).

First name, year, ref	Phase/study	n	Chemotherapy regimen	Response rates (RR)	Median progression-free survival (PFS) months	Median overall survival (OS) months	Outcome
Vogelzang, 2003 (45)	III	226	Cisplatin + pemetrexed	41.3%	5.7	12.1	Satisfactory, superior to cisplatin
Van Meerbeeck, 2005 (45)	III	126	Cisplatin + raltitrexed	23.6%	–	11.4	Satisfactory, superior to cisplatin alone
Ceresoli et al. 2006 (46)	II	102	Carboplatin plus pemetrexed	18.6%	6.5	12.7	Satisfactory, combination active and well tolerated
Obasaju, 2007 (47)	EAP	728	Cisplatin + pemetrexed	21%	–	10.8	Satisfactory, MPM patients experience a response or stable disease
Santoro, 2008 (48)	EAP	861	Cisplatin + pemetrexed	22%	–	–	Satisfactory, 1-year survival rates
Hillerdal, 2008 (49)	II	173	Carboplatin + gemcitabine + liposomal doxorubicin	33%	–	13	Satisfactory, high number of responses and long survival, and a low toxicity